造血细胞移植及其他血液恶性肿瘤治疗患者的棘白菌素类预防用药
抗真菌预防是接受高强度化疗或造血细胞移植(HCT)的血液恶性肿瘤患者的标准治疗。唑类预防可减少侵袭性真菌感染并可能降低死亡率,但存在突破性感染、药代动力学变异、药物相互作用和不良事件等问题。棘白菌素类对念珠菌属(包括部分唑类耐药菌)高度活性,对曲霉属也有一定临床活性,尽管需每日静脉给药,但安全性好且药代动力学更可预测。临床数据支持棘白菌素类用于血液病和HCT患者的抗真菌预防,但证据不如唑类充分;支持用于HCT后显著移植物抗宿主病(GvHD)患者的证据稀少。棘白菌素类是唑类及其他药物用于高强度化疗或HCT患者抗真菌预防的合理替代方案,但显著GvHD患者除外。
要点
- 唑类预防是接受高强度化疗或HCT血液恶性肿瘤患者的标准治疗,可减少侵袭性真菌感染并可能降低死亡率。
- 棘白菌素类对念珠菌属(包括部分唑类耐药菌)高度活性,对曲霉属也有一定临床活性,安全性好且药代动力学更可预测。
- 临床数据支持棘白菌素类用于血液病和HCT患者的抗真菌预防,但证据不如唑类充分;支持用于HCT后显著GvHD患者的证据稀少。
核心结论
- 棘白菌素类是唑类及其他药物用于接受高强度化疗的血液恶性肿瘤患者或接受HCT患者抗真菌预防的合理替代方案,但显著GvHD患者除外。
主要发现
- 唑类预防可减少侵袭性真菌感染并可能降低死亡率,但仍出现突破性感染,且使用有时因药代动力学变异、药物相互作用、不良事件及其他问题而复杂化。
- 棘白菌素类对念珠菌属(包括部分唑类耐药菌)高度活性,对曲霉属也有一定临床活性。
- 目前批准的棘白菌素类需每日静脉给药,但安全性好且药代动力学较具抗霉菌活性的唑类更可预测。
- 临床数据支持棘白菌素类用于血液病和HCT患者抗真菌预防的有效性和安全性,但数据不如唑类充分。
- 支持棘白菌素类用于HCT后显著GvHD患者抗真菌预防的证据稀少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 棘白菌素类用于抗真菌预防的临床数据不如唑类充分。
- 支持棘白菌素类用于HCT后显著GvHD患者抗真菌预防的证据稀少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antifungal prophylaxis is the standard of care for patients undergoing intensive chemotherapy for haematological malignancy or haematopoietic cell transplantation (HCT). Prophylaxis with azoles reduces invasive fungal infections and may reduce mortality. However, breakthrough infections still occur, and the use of azoles is sometimes complicated by pharmacokinetic variability, drug interactions, adverse events and other issues. Echinocandins are highly active against Candida species, including some organisms resistant to azoles, and have some clinical activity against Aspergillus species as well. Although currently approved echinocandins require daily intravenous administration, the drugs have a favourable safety profile and more predictable pharmacokinetics than mould-active azoles. Clinical data support the efficacy and safety of echinocandins for antifungal prophylaxis in haematology and HCT patients, though data are less robust than for azoles. Notably, sparse evidence exists supporting the use of echinocandins as antifungal prophylaxis for patients with significant graft-versus-host disease (GvHD) after HCT. Two drugs that target (1,3)-β-d-glucan are in development, including an oral glucan synthase inhibitor and an echinocandin with unique pharmacokinetics permitting subcutaneous and weekly administration. Echinocandins are a reasonable alternative to azoles and other agents for antifungal prophylaxis in patients undergoing intensive chemotherapy for haematological malignancy or those receiving HCT, excluding those with significant GvHD.
引用
- Epstein DJ, Seo SK, Brown JM, et al. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. J Antimicrob Chemother. 2018. PMID: 29304213. doi:10.1093/jac/dkx450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。